Ironwood Pharmaceuticals IRWD North America — Research And Development Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ironwood Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Ironwood Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091987
During the three and six months ended June 30, 2026, the Company incurred $2.4 million and $3.7 million, respectively, in total research and development expenses under the linaclotide collaboration for North America. During the three and six months ended June 30, 2025, the Company incurred $1.4 million and $3.2 million, respectively, in total research and development expenses under the linaclotide collaboration for North America. As a result of the research and development cost-sharing provisions of the linaclotide collaboration for North America, the Company incurred $0.1 million and $0.3 million in incremental research and development costs during the three and six months ended June 30, 2026, respectively, and incurred $1.7 million, and $2.8 million in incremental research and development costs during the three and six months ended June 30, 2025, respectively, to reflect the obligations of each party under the collaboration to bear 50% of the development costs incurred.
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Ironwood Pharmaceuticals's north america — research and development expense?
- Ironwood Pharmaceuticals (IRWD) reported north america — research and development expense of $2.4M in Q2 2026.
- How has Ironwood Pharmaceuticals's north america — research and development expense changed year-over-year?
- Ironwood Pharmaceuticals's north america — research and development expense increased by 71.4% year-over-year, from $1.4M to $2.4M.
- What is the long-term trend for Ironwood Pharmaceuticals's north america — research and development expense?
- Over 4 years (2021 to 2025), Ironwood Pharmaceuticals's north america — research and development expense has grown at a -2.2% compound annual growth rate (CAGR), from $8.2M to $7.5M.
- What does north america — research and development expense mean?
- This metric represents the total costs incurred by the North American segment for research and development activities, including clinical trials, drug discovery, and regulatory filings. It reflects the company's commitment to innovation and the long-term pipeline development within this specific geographic market.
Ask your AI about Ironwood Pharmaceuticals's north america — research and development expense.
Connect your AI assistant and compare it to peers, right in your chat.
